» Articles » PMID: 35327637

Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation

Overview
Journal Biomolecules
Publisher MDPI
Date 2022 Mar 25
PMID 35327637
Authors
Affiliations
Soon will be listed here.
Abstract

Background: COVID-19 is an infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Many COVID-19 patients require invasive mechanical ventilation (IMV) while others, even with acute respiratory failure, do not (NIMV). Therefore, we aimed to evaluate serum levels of MMP-7 and molecules related to exhausted T-cells as potential biomarkers to differentiate between IMV and NIMV patients. Methods: 105 patients diagnosed with COVID-19 and confirmed by RT-PCR for SARS-CoV-2 were divided into two groups according to the requirement for IMV. Serum levels of sPD-L1, sPD-L2, sTIM-3, sGal-9 and sMMP-7 were quantified by ELISA and correlated with clinical data. Twelve patients were followed up after eight months to compare the levels of the biomarkers between acute disease and post-COVID-19. Results: IMV patients experienced a lower PaO2/FiO2 (p < 0.0001) and a longer hospital stay (p < 0.0001), and exhibited higher levels of sPD-L1 (p < 0.05), sTIM-3 (p < 0.01) and sMMP-7 (p < 0.0001) when compared with NIMV patients. According to a ROC analysis, sMMP-7 had the highest sensitivity (78%) and specificity (76%) with a cut point of 4.5 ng/mL, followed by sTIM-3 and sPD-L1. Eight months post-COVID-19, IMV patients displayed a significant decrease in the initially high levels of sPD-L1, sTIM-3 and sGal-9, while sPD-L2 was increased, and sMMP-7 was unchanged. Conclusion: Circulating levels of sPD-L1, sTIM-3 and sMMP-7 are potential biomarkers of disease severity to distinguish patients requiring IMV. MMP-7 could also be a marker for the persistence of lung lesions post-COVID-19.

Citing Articles

Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.

Canny S, Stanaway I, Holton S, Mitchem M, ORourke A, Pribitzer S Crit Care Explor. 2025; 7(2):e1203.

PMID: 39888602 PMC: 11789895. DOI: 10.1097/CCE.0000000000001203.


Utility of Protein Markers in COVID-19 Patients.

Alicia L, Maria Angeles O, Desiree M, Maximino R, Marilina G Int J Mol Sci. 2025; 26(2).

PMID: 39859366 PMC: 11766239. DOI: 10.3390/ijms26020653.


Unlocking the Potential of RNA Sequencing in COVID-19: Toward Accurate Diagnosis and Personalized Medicine.

Eldien H, Almaeen A, El Fath A, Taha A, Ahmed R, Elfadil H Diagnostics (Basel). 2025; 15(2).

PMID: 39857114 PMC: 11763845. DOI: 10.3390/diagnostics15020229.


TIM3 in COVID-19; A potential hallmark?.

Zamani M, Sacha P Heliyon. 2025; 10(23):e40386.

PMID: 39759854 PMC: 11700678. DOI: 10.1016/j.heliyon.2024.e40386.


Precision disease management: prognostic biomarker for chronic lung damage in long COVID.

Oo A, Chu J ERJ Open Res. 2024; 10(6).

PMID: 39624388 PMC: 11610080. DOI: 10.1183/23120541.00647-2024.


References
1.
Martin-Quiros A, Maroun-Eid C, Avendano-Ortiz J, Lozano-Rodriguez R, Quiroga J, Terron V . Potential Role of the Galectin-9/TIM-3 Axis in the Disparate Progression of SARS-CoV-2 in a Married Couple: A Case Report. Biomed Hub. 2021; 6(1):48-58. PMC: 8089458. DOI: 10.1159/000514727. View

2.
Tang R, Rangachari M, Kuchroo V . Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. Semin Immunol. 2019; 42:101302. DOI: 10.1016/j.smim.2019.101302. View

3.
Xiao W, Mindrinos M, Seok J, Cuschieri J, Cuenca A, Gao H . A genomic storm in critically injured humans. J Exp Med. 2011; 208(13):2581-90. PMC: 3244029. DOI: 10.1084/jem.20111354. View

4.
Francisco L, Salinas V, Brown K, Vanguri V, Freeman G, Kuchroo V . PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206(13):3015-29. PMC: 2806460. DOI: 10.1084/jem.20090847. View

5.
Chun H, Coutavas E, Pine A, Lee A, Yu V, Shallow M . Immunofibrotic drivers of impaired lung function in postacute sequelae of SARS-CoV-2 infection. JCI Insight. 2021; 6(14). PMC: 8410030. DOI: 10.1172/jci.insight.148476. View